AChR-specific immunosuppressive therapy of myasthenia gravis

Biochemical Pharmacology

Volumn 97, Issue 4, 2015, Pages 609-619

  Luo, Jie ^a   Lindstrom, Jon ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acetylcholine receptor; Antibody; Cytoplasmic domain; EAMG; Immunosuppression

Indexed keywords

CHOLINERGIC RECEPTOR; IMMUNOSUPPRESSIVE AGENT; AUTOANTIBODY;

CLINICAL EFFECTIVENESS; CYTOPLASM; DRUG POTENCY; DRUG SAFETY; EXTRACELLULAR MATRIX; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MAIN IMMUNOGENIC REGION; MUCOSAL IMMUNITY; MULTICENTER STUDY (TOPIC); MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; METABOLISM; PROTEIN TERTIARY STRUCTURE; VACCINATION;

ANIMALS; AUTOANTIBODIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYASTHENIA GRAVIS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CHOLINERGIC; VACCINATION;

EID: 84943351622     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2015.07.011     Document Type: Review

References (120)

1. B.M. Conti-Fine, M. Milani, and H.J. Kaminski Myasthenia gravis: past, present, and future J. Clin. Invest. 116 2006 2843 2854
2. D.B. Drachman Myasthenia gravis N. Engl. J. Med. 330 1994 1797 1810
3. J.M. Lindstrom Acetylcholine receptors and myasthenia Muscle Nerve 23 2000 453 477
4. A. Vincent, J. Palace, and D. Hilton-Jones Myasthenia gravis Lancet 357 2001 2122 2128
5. J.C. Keesey Clinical evaluation and management of myasthenia gravis Muscle Nerve 29 2004 484 505
6. L.H. Phillips The epidemiology of myasthenia gravis Semin. Neurol. 24 2004 17 20
7. W. Hoch, J. McConville, S. Helms, J. Newsom-Davis, A. Melms, and A. Vincent Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies Nat. Med. 7 2001 365 368
8. B. Zhang, J.S. Tzartos, M. Belimezi, S. Ragheb, B. Bealmear, R.A. Lewis, and et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis Arch. Neurol. 69 2012 445 451
9. P. Cufi, N. Dragin, J.M. Weiss, P. Martinez-Martinez, M.H. De Baets, R. Roussin, and et al. Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis Ann. Neurol. 73 2013 281 293
10. Z. Zagoriti, M.E. Kambouris, G.P. Patrinos, S.J. Tzartos, and K. Poulas Recent advances in genetic predisposition of myasthenia gravis Biomed. Res. Int. 2013 2013 404053
11. A.M. Gomez, J. Van Den Broeck, K. Vrolix, S.P. Janssen, M.A. Lemmens, E. Van Der Esch, and et al. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction Autoimmunity 43 2010 353 370
12. J.M. Lindstrom, A.G. Engel, M.E. Seybold, V.A. Lennon, and E.H. Lambert Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies J. Exp. Med. 144 1976 739 753
13. J. Newsom-Davis, S.G. Wilson, A. Vincent, and C.D. Ward Long-term effects of repeated plasma exchange in myasthenia gravis Lancet 1 1979 464 468
14. G. Kordas, G. Lagoumintzis, S. Sideris, K. Poulas, and S.J. Tzartos Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients PLoS One 9 2014 e108327
15. S.J. Tzartos, T. Barkas, M.T. Cung, A. Mamalaki, M. Marraud, P. Orlewski, and et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor Immunol. Rev. 163 1998 89 120
16. A.G. Engel Myasthenia gravis and myasthenic syndromes Ann. Neurol. 16 1984 519 534
17. A.G. Engel, and K. Arahata The membrane attack complex of complement at the endplate in myasthenia gravis Ann. N. Y. Acad. Sci. 505 1987 326 332
18. D.B. Drachman, C.W. Angus, R.N. Adams, J.D. Michelson, and G.J. Hoffman Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation N. Engl. J. Med. 298 1978 1116 1122
19. D.B. Drachman, R.N. Adams, L.F. Josifek, and S.G. Self Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis N. Engl. J. Med. 307 1982 769 775
20. A. Alshekhlee, J.D. Miles, B. Katirji, D.C. Preston, and H.J. Kaminski Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals Neurology 72 2009 1548 1554
21. A. Diaz, E. Black, and J. Dunning Is thymectomy in non-thymomatous myasthenia gravis of any benefit Interact. Cardiovasc. Thorac. Surg. 18 2014 381 389
22. J. Newsom-Davis, G. Cutter, G.I. Wolfe, H.J. Kaminski, A. Jaretzki 3rd, G. Minisman, and et al. Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone Ann. N. Y. Acad. Sci. 1132 2008 344 347
23. A.M. Gomez, K. Vrolix, P. Martinez-Martinez, P.C. Molenaar, M. Phernambucq, E. van der Esch, and et al. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis J. Immunol. 186 2011 2503 2513
24. A.M. Gomez, N. Willcox, P.C. Molenaar, W. Buurman, P. Martinez-Martinez, M.H. De Baets, and et al. Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis? Ann. N. Y. Acad. Sci. 1274 2012 48 59
25. R. Iorio, V. Damato, P.E. Alboini, and A. Evoli Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis J. Neurol. 262 2015 1115 1119
26. N.J. Silvestri, and G.I. Wolfe Treatment-refractory myasthenia gravis J. Clin. Neuromuscul. Dis. 15 2014 167 178
27. O. Benveniste, and D. Hilton-Jones The role of rituximab in the treatment of myasthenia gravis Eur. Neurol. Rev. 5 2010 95 100
28. R. Gold, R. Hohlfeld, and K.V. Toyka Progress in the treatment of myasthenia gravis Ther. Adv. Neurol. Disord. 1 2008 36 51
29. R. Gold, M.C. Dalakas, and K.V. Toyka Immunotherapy in autoimmune neuromuscular disorders Lancet Neurol. 2 2003 22 32
30. L. Steinman, J.T. Merrill, I.B. McInnes, and M. Peakman Optimization of current and future therapy for autoimmune diseases Nat. Med. 18 2012 59 65
31. H. Wekerle, and R. Hohlfeld Zero tolerance (to acetylcholine receptor) and ways to overcome it Ann. Neurol. 67 2010 422 424
32. V.A. Lennon, J.M. Lindstrom, and M.E. Seybold Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs J. Exp. Med. 141 1975 1365 1375
33. J.M. Lindstrom, B.L. Einarson, V.A. Lennon, and M.E. Seybold Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis J. Exp. Med. 144 1976 726 738
34. J. Luo, and J. Lindstrom Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors Autoimmunity 45 2012 245 252
35. R. Tarrab-Hazdai, A. Aharonov, I. Silman, S. Fuchs, and O. Abramsky Experimental autoimmune myasthenia induced in monkeys by purified acetylcholine receptor Nature 256 1975 128 130
36. E. Toro-Goyco, E.M. Cora, M.J. Kessler, and M. Martinez-Carrion Induction of experimental myasthenia gravis in rhesus monkeys: a model for the study of the human disease P. R. Health Sci. J. 5 1986 13 18
37. H. Link, and B.G. Xiao Rat models as tool to develop new immunotherapies Immunol. Rev. 184 2001 117 128
38. J.M. Lindstrom, V.A. Lennon, M.E. Seybold, and S. Whittingham Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects Ann. N. Y. Acad. Sci. 274 1976 254 274
39. S. Tzartos, S. Hochschwender, P. Vasquez, and J. Lindstrom Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor J. Neuroimmunol. 15 1987 185 194
40. K.V. Toyka, D.B. Brachman, A. Pestronk, and I. Kao Myasthenia gravis: passive transfer from man to mouse Science 190 1975 397 399
41. K.V. Toyka, D.B. Drachman, D.E. Griffin, A. Pestronk, J.A. Winkelstein, K.H. Fishbeck, and et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice N. Engl. J. Med. 296 1977 125 131
42. M. van der Neut Kolfschoten, J. Schuurman, M. Losen, W.K. Bleeker, P. Martinez-Martinez, E. Vermeulen, and et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange Science 317 2007 1554 1557
43. J. Lindstrom Autoimmune response to acetylcholine receptors in myasthenia gravis and its animal model Adv. Immunol. 27 1979 1 50
44. S.J. Tzartos, and J.M. Lindstrom Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits Proc. Natl. Acad. Sci. U. S. A. 77 1980 755 759
45. S.J. Tzartos, M.E. Seybold, and J.M. Lindstrom Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies Proc. Natl. Acad. Sci. U. S. A. 79 1982 188 192
46. S. Tzartos, L. Langeberg, S. Hochschwender, and J. Lindstrom Demonstration of a main immunogenic region on acetylcholine receptors from human muscle using monoclonal antibodies to human receptor FEBS Lett. 158 1983 116 118
47. S.M. Sine End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease Physiol. Rev. 92 2012 1189 1234
48. S.C. Froehner Identification of exposed and buried determinants of the membrane-bound acetylcholine receptor from Torpedo californica Biochemistry 20 1981 4905 4915
49. R. Beroukhim, and N. Unwin Three-dimensional location of the main immunogenic region of the acetylcholine receptor Neuron 15 1995 323 331
50. K. Brejc, W.J. van Dijk, R.V. Klaassen, M. Schuurmans, J. van Der Oost, A.B. Smit, and et al. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors Nature 411 2001 269 276
51. N. Unwin Refined structure of the nicotinic acetylcholine receptor at 4Å resolution J. Mol. Biol. 346 2005 967 989
52. J. Luo, P. Taylor, M. Losen, M.H. de Baets, G.D. Shelton, and J. Lindstrom Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity J. Neurosci. 29 2009 13898 13908
53. M.S. Saedi, R. Anand, W.G. Conroy, and J. Lindstrom Determination of amino acids critical to the main immunogenic region of intact acetylcholine receptors by in vitro mutagenesis FEBS Lett. 267 1990 55 59
54. W.G. Conroy, M.S. Saedi, and J. Lindstrom TE671 cells express an abundance of a partially mature acetylcholine receptor α subunit which has characteristics of an assembly intermediate J. Biol. Chem. 265 1990 21642 21651
55. J. Luo, and J. Lindstrom Antigenic structure of the human muscle nicotinic acetylcholine receptor main immunogenic region J. Mol. Neurosci. 40 2010 217 220
56. J. Lindstrom, and J. Luo Myasthenogenicity of the main immunogenic region Ann. N. Y. Acad. Sci. 1274 2012 9 13
57. A.G. Engel, M. Tsujihata, E.H. Lambert, J.M. Lindstrom, and V.A. Lennon Experimental autoimmune myasthenia gravis: a sequential and quantitative study of the neuromuscular junction ultrastructure and electrophysiologic correlations J. Neuropathol. Exp. Neurol. 35 1976 569 587
58. A.G. Engel, M. Tsujihata, J.M. Lindstrom, and V.A. Lennon The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study Ann. N. Y. Acad. Sci. 274 1976 60 79
59. K. Sahashi, A.G. Engel, E.H. Lambert, and F.M. Howard Jr. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis J. Neuropathol. Exp. Neurol. 39 1980 160 172
60. K. Sahashi, A.G. Engel, J.M. Linstrom, E.H. Lambert, and V.A. Lennon Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis J. Neuropathol. Exp. Neurol. 37 1978 212 223
61. T. Feferman, S.H. Im, S. Fuchs, and M.C. Souroujon Breakage of tolerance to hidden cytoplasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis J. Neuroimmunol. 140 2003 153 158
62. M. Criado, J. Mulet, M. Castillo, S. Gerber, S. Sala, and F. Sala The loop between β-strands β2 and β3 and its interaction with the N-terminal α-helix is essential for biogenesis of α7 nicotinic receptors J. Neurochem. 112 2010 103 111
63. D. Bartfeld, and S. Fuchs Specific immunosuppression of experimental autoimmune myasthenia gravis by denatured acetylcholine receptor Proc. Natl. Acad. Sci. U. S. A. 75 1978 4006 4010
64. C.G. Ma, G.X. Zhang, B.G. Xiao, J. Link, T. Olsson, and H. Link Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor J. Neuroimmunol. 58 1995 51 60
65. S. Okumura, K. McIntosh, and D.B. Drachman Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis Ann. Neurol. 36 1994 704 713
66. Z.Y. Wang, J. Qiao, and H. Link Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor J. Neuroimmunol. 44 1993 209 214
67. F.D. Shi, X.F. Bai, H.L. Li, Y.M. Huang, P.H. Van der Meide, and H. Link Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals Clin. Exp. Immunol. 111 1998 506 512
68. H. Loutrari, A. Kokla, N. Trakas, and S.J. Tzartos Expression of human-Torpedo hybrid acetylcholine receptor (AChR) for analysing the subunit specificity of antibodies in sera from patients with myasthenia gravis (MG) Clin. Exp. Immunol 109 1997 538 546
69. D. Barchan, M.C. Souroujon, S.H. Im, C. Antozzi, and S. Fuchs Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor α-subunit Proc. Natl. Acad. Sci. U. S. A. 96 1999 8086 8091
70. S. Fuchs, R. Aricha, D. Reuveni, and M.C. Souroujon Experimental Autoimmune Myasthenia Gravis (EAMG): from immunochemical characterization to therapeutic approaches J. Autoimmun. 54 2014 51 59
71. S.H. Im, D. Barchan, S. Fuchs, and M.C. Souroujon Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment J. Clin. Invest. 104 1999 1723 1730
72. S.H. Im, D. Barchan, S. Fuchs, and M.C. Souroujon Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis J. Neuroimmunol. 111 2000 161 168
73. P.K. Maiti, T. Feferman, S.H. Im, M.C. Souroujon, and S. Fuchs Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment J. Neuroimmunol. 152 2004 112 120
74. S.H. Im, D. Barchan, M.C. Souroujon, and S. Fuchs Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis J. Immunol. 165 2000 3599 3605
75. H.J. Yi, C.S. Chae, J.S. So, S.J. Tzartos, M.C. Souroujon, S. Fuchs, and et al. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor Mol. Immunol. 46 2008 192 201
76. J. Lindstrom, X. Peng, A. Kuryatov, E. Lee, R. Anand, V. Gerzanich, and et al. Molecular and antigenic structure of nicotinic acetylcholine receptors Ann. N. Y. Acad. Sci. 841 1998 71 86
77. M.P. Protti, A.A. Manfredi, R.M. Horton, M. Bellone, and B.M. Conti-Tronconi Myasthenia gravis: recognition of a human autoantigen at the molecular level Immunol. Today 14 1993 363 368
78. J. Lindstrom, J. Luo, and A. Kuryatov Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains Ann. N. Y. Acad. Sci. 1132 2008 29 41
79. J. Luo, A. Kuryatov, and J.M. Lindstrom Specific immunotherapy of experimental myasthenia gravis by a novel mechanism Ann. Neurol. 67 2010 441 451
80. M.Z. Atassi, K.H. Ruan, K. Jinnai, M. Oshima, and T. Ashizawa Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide Proc. Natl. Acad. Sci. U. S. A. 89 1992 5852 5856
81. F. Baggi, F. Andreetta, E. Caspani, M. Milani, R. Longhi, R. Mantegazza, and et al. Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis J. Clin. Invest. 104 1999 1287 1295
82. P.I. Karachunski, N.S. Ostlie, D.K. Okita, and B.M. Conti-Fine Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences J. Clin. Invest. 100 1997 3027 3035
83. P.I. Karachunski, N.S. Ostlie, D.K. Okita, R. Garman, and B.M. Conti-Fine Subcutaneous administration of T-epitope sequences of the acetylcholine receptor prevents experimental myasthenia gravis J. Neuroimmunol. 93 1999 108 121
84. M. Shenoy, M. Oshima, M.Z. Atassi, and P. Christadoss Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region α 146-162 of acetylcholine receptor Clin. Immunol. Immunopathol. 66 1993 230 238
85. B. Wu, C. Deng, E. Goluszko, and P. Christadoss Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis J. Immunol. 159 1997 3016 3023
86. S. Hawke, H. Matsuo, M. Nicolle, G. Malcherek, A. Melms, and N. Willcox Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting Immunol. Today 17 1996 307 311
87. M.C. Dalakas Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future Ann. N. Y. Acad. Sci. 1274 2012 1 8
88. C.A. Sabatos-Peyton, J. Verhagen, and D.C. Wraith Antigen-specific immunotherapy of autoimmune and allergic diseases Curr. Opin. Immunol. 22 2010 609 615
89. E. Blanas, F.R. Carbone, J. Allison, J.F. Miller, and W.R. Heath Induction of autoimmune diabetes by oral administration of autoantigen Science 274 1996 1707 1709
90. B.G. Xiao, and H. Link Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases Clin. Immunol. Immunopathol. 85 1997 119 128
91. V.A. Lennon, E.H. Lambert, K.R. Leiby, T.B. Okarma, and S. Talib Recombinant human acetylcholine receptor α-subunit induces chronic experimental autoimmune myasthenia gravis J. Immunol. 146 1991 2245 2248
92. J. Lindstrom, B. Einarson, and J. Merlie Immunization of rats with polypeptide chains from Torpedo acetylcholine receptor causes an autoimmune response to receptors in rat muscle Proc. Natl. Acad. Sci. U. S. A. 75 1978 769 773
93. M.C. Dalakas Novel future therapeutic options in myasthenia gravis Autoimmun. Rev. 12 2013 936 941
94. J. Luo, and J.M. Lindstrom Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis J. Immunol. 193 2014 5044 5055
95. D.H. Cribbs, A. Ghochikyan, V. Vasilevko, M. Tran, I. Petrushina, N. Sadzikava, and et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with β-amyloid Int. Immunol. 15 2003 505 514
96. F.J. Dixon, H. Jacot-Guillarmod, and P.J. McConahey The effect of passively administered antibody on antibody synthesis J. Exp. Med. 125 1967 1119 1135
97. D. Brinc, G.A. Denomme, and A.H. Lazarus Mechanisms of anti-d action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models Curr. Opin. Hematol. 16 2009 488 496
98. B. Heyman Regulation of antibody responses via antibodies, complement, and Fc receptors Annu. Rev. Immunol. 18 2000 709 737
99. D. Na, D. Kim, and D. Lee Mathematical modeling of humoral immune response suppression by passively administered antibodies in mice J. Theor. Biol. 241 2006 830 851
100. K. Sahashi, A.G. Engel, E.H. Lambert, and F.M. Howard Jr. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis J. Neuropathol. Exp. Neurol. 39 1980 160 172
101. Z. Xiang, A.J. Cutler, R.J. Brownlie, K. Fairfax, K.E. Lawlor, E. Severinson, and et al. FcγRIIb controls bone marrow plasma cell persistence and apoptosis Nat. Immunol. 8 2007 419 429
102. A.K. Abbas, K.M. Murphy, and A. Sher Functional diversity of helper T lymphocytes Nature 383 1996 787 793
103. C.M. Hammers, K. Bieber, K. Kalies, D. Banczyk, C.T. Ellebrecht, S.M. Ibrahim, and et al. Complement-fixing anti-type VII collagen antibodies are induced in Th1-polarized lymph nodes of epidermolysis bullosa acquisita-susceptible mice J. Immunol. 187 2011 5043 5050
104. A. Rodgaard, F.C. Nielsen, R. Djurup, F. Somnier, and S. Gammeltoft Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3 Clin. Exp. Immunol. 67 1987 82 88
105. + regulatory T cells in systemic autoimmune diseases Autoimmun. Rev. 10 2011 744 755
106. ++ T cells in patients with myasthenia gravis is associated with phenotypic changes and STAT5 signaling: 1,25-dihydroxyvitamin D3 modulates the suppressor activity J. Neuroimmunol. 281 2015 51 60
107. + T cells in the thymus of patients with autoimmune myasthenia gravis Blood 105 2005 735 741
108. + T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment Immunology 116 2005 134 141
109. A. Gradolatto, D. Nazzal, F. Truffault, J. Bismuth, E. Fadel, M. Foti, and et al. Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: Roles of IL-17 and TNF-α J. Autoimmun. 52 2014 53 63
110. + B cells and soluble ICAM-1 in myasthenia gravis Clin. Immunol. 126 2008 180 188
111. C. Luther, E. Adamopoulou, C. Stoeckle, V. Brucklacher-Waldert, D. Rosenkranz, L. Stoltze, and et al. Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients J. Immunol. 183 2009 841 848
112. low/- T cells in patients with myasthenia gravis Clin. Immunol. 145 2012 209 223
113. R. Aricha, T. Feferman, S. Fuchs, and M.C. Souroujon Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis J. Immunol. 180 2008 2132 2139
114. S. Gertel-Lapter, K. Mizrachi, S. Berrih-Aknin, S. Fuchs, and M.C. Souroujon Impairment of regulatory T cells in myasthenia gravis: studies in an experimental model Autoimmun. Rev. 12 2013 894 903
115. A.M. Faria, and H.L. Weiner Oral tolerance: therapeutic implications for autoimmune diseases Clin. Dev. Immunol. 13 2006 143 157
116. + regulatory T cells control humoral autoimmunity by suppressing the development of long-lived plasma cells J. Immunol. 186 2011 1546 1553
117. P. McGuirk, and K.H. Mills Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases Trends Immunol. 23 2002 450 455
118. Y. Kondo, and T. Shimosegawa Significant roles of regulatory T cells and myeloid derived suppressor cells in hepatitis B virus persistent infection and hepatitis B virus-related HCCs Int. J. Mol. Sci. 16 2015 3307 3322
119. P. Marrack, A.S. McKee, and M.W. Munks Towards an understanding of the adjuvant action of aluminium Nat. Rev. Immunol. 9 2009 287 293
120. E.G. Hughes, X. Peng, A.J. Gleichman, M. Lai, L. Zhou, R. Tsou, and et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis J. Neurosci. 30 2010 5866 5875